Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea

Natalie R Stokes,1 Brett W Dietz,1 Jackson J Liang2 1Perelman School of Medicine, University of Pennsylvania, 2Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USAAbstract: Dyspnea is a common chief complaint in the emergency department, with over 4 mil...

Full description

Bibliographic Details
Main Authors: Stokes NR, Dietz BW, Liang JJ
Format: Article
Language:English
Published: Dove Medical Press 2016-05-01
Series:Open Access Emergency Medicine
Subjects:
Online Access:https://www.dovepress.com/cardiopulmonary-laboratory-biomarkers-in-the-evaluation-of-acute-dyspn-peer-reviewed-article-OAEM
id doaj-fc767158c5fc4bd995571fac173a0c76
record_format Article
spelling doaj-fc767158c5fc4bd995571fac173a0c762020-11-24T21:08:16ZengDove Medical PressOpen Access Emergency Medicine1179-15002016-05-012016Issue 1354526957Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspneaStokes NRDietz BWLiang JJNatalie R Stokes,1 Brett W Dietz,1 Jackson J Liang2 1Perelman School of Medicine, University of Pennsylvania, 2Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USAAbstract: Dyspnea is a common chief complaint in the emergency department, with over 4 million visits annually in the US. Establishing the correct diagnosis can be challenging, because the subjective sensation of dyspnea can result from a wide array of underlying pathology, including pulmonary, cardiac, neurologic, psychiatric, toxic, and metabolic disorders. Further, the presence of dyspnea is linked with increased mortality in a variety of conditions, and misdiagnosis of the cause of dyspnea leads to poor patient-level outcomes. In combination with the history and physical, efficient, and focused use of laboratory studies, the various cardiopulmonary biomarkers can be useful in establishing the correct diagnosis and guiding treatment decisions in a timely manner. Use and interpretation of such tests must be guided by the clinical context, as well as an understanding of the current evidence supporting their use. This review discusses current standards and research regarding the use of established and emerging cardiopulmonary laboratory markers in the evaluation of acute dyspnea, focusing on recent evidence assessing the diagnostic and prognostic utility of various tests. These markers include brain natriuretic peptide (BNP) and N-terminal prohormone (NT-proBNP), mid-regional peptides proatrial NP and proadrenomedullin, cardiac troponins, D-dimer, soluble ST2, and galectin 3, and included is a discussion on the use of arterial and venous blood gases.Keywords: cardiopulmonary, emergency, heart failure, troponin, BNP, galectin 3, MR-proANP, MR-proADMhttps://www.dovepress.com/cardiopulmonary-laboratory-biomarkers-in-the-evaluation-of-acute-dyspn-peer-reviewed-article-OAEMDyspnea
collection DOAJ
language English
format Article
sources DOAJ
author Stokes NR
Dietz BW
Liang JJ
spellingShingle Stokes NR
Dietz BW
Liang JJ
Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
Open Access Emergency Medicine
Dyspnea
author_facet Stokes NR
Dietz BW
Liang JJ
author_sort Stokes NR
title Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
title_short Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
title_full Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
title_fullStr Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
title_full_unstemmed Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
title_sort cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea
publisher Dove Medical Press
series Open Access Emergency Medicine
issn 1179-1500
publishDate 2016-05-01
description Natalie R Stokes,1 Brett W Dietz,1 Jackson J Liang2 1Perelman School of Medicine, University of Pennsylvania, 2Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USAAbstract: Dyspnea is a common chief complaint in the emergency department, with over 4 million visits annually in the US. Establishing the correct diagnosis can be challenging, because the subjective sensation of dyspnea can result from a wide array of underlying pathology, including pulmonary, cardiac, neurologic, psychiatric, toxic, and metabolic disorders. Further, the presence of dyspnea is linked with increased mortality in a variety of conditions, and misdiagnosis of the cause of dyspnea leads to poor patient-level outcomes. In combination with the history and physical, efficient, and focused use of laboratory studies, the various cardiopulmonary biomarkers can be useful in establishing the correct diagnosis and guiding treatment decisions in a timely manner. Use and interpretation of such tests must be guided by the clinical context, as well as an understanding of the current evidence supporting their use. This review discusses current standards and research regarding the use of established and emerging cardiopulmonary laboratory markers in the evaluation of acute dyspnea, focusing on recent evidence assessing the diagnostic and prognostic utility of various tests. These markers include brain natriuretic peptide (BNP) and N-terminal prohormone (NT-proBNP), mid-regional peptides proatrial NP and proadrenomedullin, cardiac troponins, D-dimer, soluble ST2, and galectin 3, and included is a discussion on the use of arterial and venous blood gases.Keywords: cardiopulmonary, emergency, heart failure, troponin, BNP, galectin 3, MR-proANP, MR-proADM
topic Dyspnea
url https://www.dovepress.com/cardiopulmonary-laboratory-biomarkers-in-the-evaluation-of-acute-dyspn-peer-reviewed-article-OAEM
work_keys_str_mv AT stokesnr cardiopulmonarylaboratorybiomarkersintheevaluationofacutedyspnea
AT dietzbw cardiopulmonarylaboratorybiomarkersintheevaluationofacutedyspnea
AT liangjj cardiopulmonarylaboratorybiomarkersintheevaluationofacutedyspnea
_version_ 1716760228602576896